Revaree Review 2026: Does It Work, What It Really Costs, and Who Should Skip It
Before you commit to a vaginal moisturizer
Sort vaginal dryness from urinary symptoms, bleeding, pain, or a need for clinician-guided vaginal estrogen before paying for repeat boxes.
Revaree is a reasonable hormone-free first try for recurring vaginal dryness when condoms are not part of your contraception or STI plan. It is FDA-cleared as a Class II personal-lubricant device—not FDA-approved as a drug—and a 10-insert box lasts 20 to 30 days. Skip it for urinary symptoms, unexplained bleeding, or severe or worsening pain.
That's the verdict. Here's the part that costs people money.
We wrote this Revaree review after reading Bonafide's current product pages and policies, both FDA clearance summaries, the full 2024 randomized pilot, its trial record, the 2025 genitourinary syndrome of menopause guideline, live retail listings, and FDA adverse-event reports.
The single most useful finding is what happens when you put the box count beside the schedule on the label. A “one-month supply” covers about 30 days only at one insert every three nights. At one every two nights, the same 10-insert box runs out around day 20.
That math is not shown beside the checkout price. We show it below, then show the lowest-commitment way to find out whether the insert format fits your life without accepting a renewal first.
Revaree at a glance
Revaree is a 5 mg hyaluronic-acid vaginal insert sold without a prescription. Its strongest advantages are a hormone-free, applicator-free format and traceable FDA device clearance. Its biggest drawbacks are repeat cost, a 20-to-30-day 10-count box, direct returns limited to unopened product, and incompatibility with three common condom materials.
| Decision fact | What we verified |
|---|---|
| What it is | A 2-gram vaginal insert containing 5 mg of hyaluronic acid sodium salt in a semi-synthetic glyceride base. No listed hormone. No prescription. |
| Regulatory status | FDA-cleared Class II personal-lubricant device under 510(k) K153372. Not an FDA-approved drug. Not HRT. |
| How you use it | One insert every two to three nights, preferably at bedtime, or as directed by a clinician. Bonafide says to remain lying down for 30 minutes. |
| What one 10-count box covers | About 20 days at every-two-night use or 30 days at every-three-night use. |
| Lowest fixed cash commitment we verified | Target's 5-count box at $26.99 — no subscription. Its listing displayed a 90-day return window; the complete Target policy and item eligibility still apply. |
| Lowest live quoted unit price | SingleCare displayed $36.78 for 10 inserts with a one-time $3 signup bonus, or $3.68 each. It is an estimated, pharmacy- and location-dependent quote, not a guaranteed price. |
| Our direct-subscription balance after it works | Bonafide's quarterly plan: $129 charged at once for 30 inserts, or $4.30 each. |
| Lowest fixed direct unit price | Bonafide's six-month plan: $222 charged at once for 60 inserts, or $3.70 each. |
| Worst fixed unit value we verified | Bonafide's one-time direct box: $68 delivered for 10 inserts, or $6.80 each, before tax. |
| The main catch | Revaree is not compatible with natural rubber latex, polyurethane, or polyisoprene condoms. Direct returns are limited to unopened, unused product. |
Prices and terms verified September 2, 2026. Tax excluded. Retail stock, fulfillment, local pharmacy quotes, and coupon availability can change.
Revaree may fit you if
You want a hormone-free, applicator-free vaginal moisturizer for dryness that keeps coming back. You can use it every two to three nights at bedtime. You do not rely on natural rubber latex, polyurethane, or polyisoprene condoms. You are willing to judge the format first, then use the brand's day-30 claim and the trial's 12-week endpoint as separate checkpoints instead of expecting a five-insert box to prove the result.
Choose a different first step if
You have urinary urgency, frequency, leakage, or repeat UTIs along with the dryness. You rely on one of the condom materials in Revaree's warning. Sex hurts in a way a moisturizer has not touched. You have unexplained bleeding, unusual discharge, fever, pelvic pain, a lump, a sore, or symptoms that changed suddenly. You are pregnant or breastfeeding without guidance. You have a known almond allergy or sensitivity and were considering Revaree Plus.
Each of those changes the answer. We name the next step instead of pretending one box fits every situation.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult
What we actually verified for this Revaree review
We checked Revaree's live product page, current terms and return policy, both FDA clearance summaries, the current instructions for use, the full product-specific randomized pilot and its registry record, the 2025 AUA/SUFU/AUGS guideline, live Target listings, current prescription-discount quotes, and the brand-name reports we could locate in FDA's MAUDE database. We did not use the product or complete a purchase.
What we checked ourselves
- Bonafide's Revaree product page — prices, plan sizes, ingredients, directions, insert-count language, condom warning, and marketing citations
- Bonafide's current Revaree instructions for use — composition, schedule, storage, interactions, pregnancy/breastfeeding language, and stop-use instructions
- Bonafide's Revaree Plus page and Plus package insert — formula, prices, almond warning, directions, and condom warning
- Bonafide's terms, return policy, and HSA/FSA process
- FDA 510(k) summaries K153372 and K213220
- FDA's AccessGUDID record for Revaree, which connects the U.S. brand to the device record
- Agrawal et al., Menopause 2024, PubMed's indexed record, and ClinicalTrials.gov NCT04544475
- The AUA/SUFU/AUGS 2025 Genitourinary Syndrome of Menopause Guideline
- Target's current 5-count and 10-count listings
- SingleCare's current Revaree discount page and generic-estradiol price page
- FDA's current MAUDE pages for the Revaree and Revaree Plus reports described below
What we did not verify
- Whether Revaree works in any individual body, including ours. We did not test it.
- A completed Bonafide checkout or cancellation. We verified the published cart structure and policies, not the experience of executing either one.
- Current local tax, inventory, pickup availability, delivery time, or a guaranteed pharmacy coupon price.
- Whether Target would accept an opened product. The current listing displays a 90-day return window, but the complete Target policy and actual item eligibility control.
- Any seller's claim that a result is typical. We treat product-page percentages as company-published claims unless a peer-reviewed source supports the same endpoint.
How we sort claims
Commercial facts — price, package size, shipping, renewal, and cancellation — get a date and a source. Medical and regulatory facts come from FDA records, current product instructions, guideline bodies, or peer-reviewed literature. Editorial judgments are labeled as conclusions based on the facts immediately above them.
This is The HRT Index Verification Standard: we read every published price, separate FDA-approved from compounded and from FDA-cleared, verify availability and coverage, and re-check on a fixed schedule. We evaluate on five pillars, in this order — clinical legitimacy, care quality, medication fit, price transparency, and access. We do not publish numeric scores. A seller's star average is not our verdict.
Seller-stated versus independently verified
| Claim shoppers see | Seller-stated version | What we verified or calculated |
|---|---|---|
| “One-month supply” | Ten inserts are sold as a 30-day box | Ten inserts cover about 20 days at every-two-night use or 30 days at every-three-night use |
| FDA status | Bonafide says Revaree is FDA-cleared and a Class II medical device | FDA K153372 confirms a Class II personal-lubricant device cleared through substantial equivalence — not an FDA-approved drug |
| “91% by day 30” | Bonafide presents this as a current product claim | We verified the claim on the seller page; we did not find a matching peer-reviewed day-30 endpoint that turns it into a guaranteed response rate |
| Subscription price | Quarterly is displayed as $43 per month and six-month as $37 per month | The actual charges are $129 quarterly and $222 every six months |
| Comparable to estrogen | Product marketing leans on HA-versus-estrogen studies | The strongest product-specific trial was a small open-label pilot and was not an equivalence or noninferiority trial |
Commercial facts verified September 2, 2026. Regulatory and trial conclusions come from the FDA records and the published study linked below.
Is Revaree FDA approved?
No. Revaree is FDA-cleared, not FDA-approved. Its underlying device record is 510(k) K153372, a Class II medical device in the personal-lubricant category. FDA's public summary describes substantial equivalence and nonclinical performance testing. It does not describe a clinical efficacy trial proving that Revaree treats GSM or works as well as vaginal estrogen.
That distinction matters, but it needs to be stated accurately.
A 510(k) clearance is not an empty rubber stamp. FDA evaluates whether a device has the same intended use as a legally marketed predicate and whether any technological differences raise different questions of safety and effectiveness. Performance evidence can be part of that review. What it is not is FDA drug approval, and it is not a product-specific finding that Revaree treats every symptom grouped under genitourinary syndrome of menopause.
Bonafide currently labels Revaree as FDA-cleared and a Class II medical device. That is accurate. The trouble starts when another page translates “cleared” into “FDA approved” or turns a substantial-equivalence decision into proof of clinical equivalence with vaginal estrogen.
What's in Revaree's FDA record
| FDA record detail | Original Revaree | Revaree Plus |
|---|---|---|
| 510(k) number | K153372 | K213220 |
| Device name in the file | Repagyn vaginal suppositories | Revaree Plus vaginal suppositories |
| Applicant | Farma-Derma S.r.l., Italy | Farma-Derma S.r.l., Italy |
| Decision date | June 30, 2016 | June 21, 2022 |
| Decision | Substantially equivalent | Substantially equivalent |
| Product code | NUC — personal lubricant | NUC — personal lubricant |
| Device class | Class II | Class II |
| Market route | Sold without a prescription | Sold without a prescription |
| Predicate device | Hyalo Gyn, K094039 | Original Repagyn, K153372 |
| Cleared use | Vaginal personal lubricant intended to moisturize and lubricate around intimate activity | Same basic intended use |
| Formula in public summary | 2 g insert; 5 mg hyaluronic acid with semi-synthetic glycerides | 2 g insert; 10 mg hyaluronic acid with glycerides and sweet almond oil |
| Performance evidence described publicly | Biocompatibility, aging/shelf-life, and condom-compatibility testing | Biocompatibility and aging/shelf-life testing; condom testing not conducted |
| Condom status | Tested and found incompatible with natural rubber latex, polyurethane, and polyisoprene condoms | Not tested; current labeling says not compatible with those same materials |
| Shelf life | 24 months | 24 months |
Source: FDA K153372 summary, FDA K213220 summary, and FDA's 510(k) overview. Re-read September 2, 2026.
Three things that table tells you
One: cleared and approved are not interchangeable. The original Revaree record rests on substantial equivalence to Hyalo Gyn. Revaree Plus rests on substantial equivalence to the original. That is a legitimate regulatory pathway. It still does not convert either insert into an FDA-approved drug or prove that the product treats every GSM symptom.
Two: the cleared use is narrower than the biggest claims shoppers encounter. The FDA record places the device in the personal-lubricant category and describes moisturizing and lubrication around intimate activity. It does not clear Revaree as a treatment for urinary urgency, frequency, leakage, recurrent UTI, or the underlying tissue changes caused by low estrogen.
Bonafide does print the personal-lubricant wording in its product-page review disclaimer. That deserves credit. It is simply far below the headline, where many shoppers will never see the distinction.
Three: the condom warning reaches beyond latex. Original Revaree was tested and found incompatible with natural rubber latex, polyurethane, and polyisoprene condoms. Revaree Plus was not tested, so the current product labeling carries the same not-compatible warning. The practical instruction is identical for both products, but the evidence behind the label differs.
One final oddity: both records sit under 21 CFR 884.5300, whose regulation heading includes the word “condom.” That is a classification bucket for condoms and related personal lubricants. It does not mean Revaree is a condom, contraception, or spermicide. The product instructions say the opposite.
Does Revaree actually work for vaginal dryness?
Vaginal hyaluronic acid has real evidence as a hormone-free option for dryness, and Revaree is a credible way to use it. The strongest product-specific study is still small: 49 women were randomized, 45 contributed week-12 data, the trial was open-label and single-center, and Bonafide funded it. Both groups improved, but the pilot cannot prove equivalence to vaginal estrogen.
This is where most reviews hand you either a marketing claim or a vague sentence about “studies.” The useful answer is more specific: there is evidence for the ingredient category, there is encouraging product-specific evidence, and the strongest sales wording is still stronger than the trial design earns.
The five levels of evidence, sorted
| Evidence level | What it is | Was this exact product tested? | What it supports | What it cannot prove |
|---|---|---|---|---|
| 1. The 2024 randomized pilot | 49 randomized; 45 with week-12 data; 5 mg vaginal HA insert versus vaginal estrogen cream; open-label; single center | The registry names Revaree, and the paper describes a 5 mg insert matching original Revaree's strength | Both groups improved; the main symptom score showed no detected between-group difference | Equivalence, superiority, rare harms, or long-term results |
| 2. Trials of other vaginal HA products | Randomized and observational studies of gels, creams, and pessaries | No | Vaginal hyaluronic acid as a category can improve dryness and related symptoms | That Revaree performs identically to every other formulation |
| 3. The Revaree Plus conference abstract | Four-week, open-label, uncontrolled study with 70 completers | Plus, not original Revaree | Short-term self-reported changes with the 10 mg almond-oil formula | Comparative effectiveness, durability, or original Revaree performance |
| 4. Manufacturer surveys and product-page percentages | Voluntary, uncontrolled customer reporting | Usually the brand's product, but not a controlled trial | What surveyed customers reported | Causation, typical response, or dependable side-effect rates |
| 5. Retail and forum reviews | Individual experiences | Usually yes | Practical friction: residue, insertion, packaging, cost, and expectations | Efficacy or safety rates |
The randomized pilot that matters most
The 2024 paper was published in Menopause and registered as NCT04544475 at NYU Langone Health.
- 49 women were randomized; 45 provided data at week 12 — 23 in the vaginal-estrogen arm and 22 in the hyaluronic-acid arm.
- It was a randomized, parallel-arm pilot, open-label, and conducted at one center. There was no placebo arm.
- The main result showed no detected difference between groups on the Vulvovaginal Symptom Questionnaire at 12 weeks (P = 0.81).
- Both groups improved on the main symptom score. Pain, symptom-index, total sexual-function, and vaginal-pH measures also improved over time without a detected difference between arms.
- More than 90% in both groups reported improvement on the patient-global-impression measure; the between-group comparison was not significant.
- No treatment-related serious adverse events were reported.
- The paper states that Bonafide Health provided funding.
The paper also contains details that do not fit a clean “same as estrogen” headline. Vaginal maturation index and the lubrication subscore of the sexual-function measure favored the estrogen group. The trial was not designed or powered as a formal equivalence or noninferiority study. A small pilot can miss a real difference.
So the sentence that survives the audit is this: a 5 mg vaginal hyaluronic-acid insert produced meaningful symptom improvement over 12 weeks in this small study, and the main symptom score did not show a between-group difference. That is encouraging. It is not proof that Revaree is clinically equivalent to estrogen.
The 91% claim needs its label attached
Bonafide's current product page says 91% of women experienced relief by day 30. That is a company-published claim. The peer-reviewed pilot reports that more than 90% in both groups felt improved at week 12, and the groups did not differ significantly.
Those are not automatically the same endpoint. We do not use the day-30 91% sentence as proof of a Revaree-only effect, and we do not turn a both-groups-improved finding into an “equal to estrogen” claim.
The paper contains a confirmed documentation problem
The full 2024 article describes the hyaluronic-acid product as a 5 mg insert, yet calls it “FDA-approved.” That regulatory wording is wrong: the relevant products are FDA-cleared devices, not FDA-approved drugs.
The paper's product reference points to Revaree Plus clearance K213220, even though the intervention is described as 5 mg and Revaree Plus contains 10 mg plus sweet almond oil. The 5 mg formulation matches the original Revaree record, K153372.
That inconsistency does not erase the trial results. It does mean the paper should not be used as the authority for Revaree's FDA status or exact regulatory identity. We use the FDA files for that.
Where the other numbers on the product page come from
Bonafide publishes a source list, which is more transparent than many product pages. But “published source” does not always mean a full peer-reviewed product-specific trial.
| Marketing claim type | What sits behind it | What that means for a buyer |
|---|---|---|
| Comparisons with vaginal estrogen | A mix of studies testing other HA gels or creams, the small 2024 insert pilot, and reviews | Supports the ingredient category; does not make every formulation interchangeable |
| “91% by day 30” | Company-published product-page claim | Treat as a manufacturer claim unless the exact day-30 endpoint can be matched to a full peer-reviewed analysis |
| Early-relief percentages | Manufacturer-attributed survey or conference-abstract data | Useful for expectation-setting, not a controlled estimate of what a new buyer will experience |
| Revaree Plus percentages | Four-week, open-label, uncontrolled conference abstract | Preliminary self-reported evidence for Plus, not proof it beats original Revaree |
None of that makes the findings worthless. Conference abstracts are a normal early step. Industry funding is common and was disclosed. The problem begins only when the evidence level disappears from the sales sentence.
So — does it work?
Our editorial conclusion, based on the verified evidence above: Revaree is a reasonable hormone-free option for ongoing vaginal dryness, especially for someone who wants an over-the-counter insert and understands that the product-specific evidence is encouraging but limited.
The evidence does not support a guarantee. It cannot tell you that you will respond, that you will respond as well as you would to prescription vaginal estrogen, or that an unexplained symptom is safe to self-treat.
Sources: Agrawal et al. 2024 full text, PubMed record, ClinicalTrials.gov NCT04544475, and Chen et al. 2013.
What does Revaree really cost in 2026?
The checkout structure matters more than the displayed monthly figure. Bonafide charges $47 for 10 inserts monthly, $129 for 30 quarterly, or $222 for 60 every six months. The quarterly plan is $4.30 per insert; the six-month plan is $3.70. A live SingleCare quote was slightly lower per insert, while Target's five-count box required the least cash upfront.
The word “monthly” hides the first piece of math. The published schedule is one insert every two to three nights. Ten inserts cover roughly 20 days at one every two nights and 30 days at one every three nights.
The second piece of math is the checkout charge. Bonafide displays normalized monthly equivalents on longer plans, but it charges the quarter or six months upfront.
Original Revaree: verified price and coverage matrix
| Buying route | Cash charged now | Inserts | Cost per insert | Coverage at every 2 nights | Coverage at every 3 nights | Auto-renewal | Shipping treatment |
|---|---|---|---|---|---|---|---|
| Target 5-count | $26.99 | 5 | $5.40 | 10 days | 15 days | No | Fulfillment-dependent |
| Target 10-count | $47.99 | 10 | $4.80 | 20 days | 30 days | No | Fulfillment-dependent |
| SingleCare live quote | $36.78 estimated | 10 | $3.68 | 20 days | 30 days | No | Pharmacy-dependent |
| SingleCare without the one-time $3 bonus | $39.78 estimated | 10 | $3.98 | 20 days | 30 days | No | Pharmacy-dependent |
| Bonafide one-time direct | $68 delivered | 10 | $6.80 | 20 days | 30 days | No | $63 product + $5 standard shipping |
| Bonafide monthly | $47 | 10 | $4.70 | 20 days | 30 days | Yes | Free standard shipping |
| Bonafide quarterly | $129 | 30 | $4.30 | 60 days | 90 days | Yes | Free standard shipping |
| Bonafide every 6 months | $222 | 60 | $3.70 | 120 days | 180 days | Yes | Free standard shipping |
Verified September 2, 2026. Tax excluded. SingleCare displayed a regular retail estimate of about $67.23 and the coupon figures above; its price is an estimate tied to pharmacy, location, and coupon availability, not a guaranteed checkout price. Target stock, fulfillment, and shipping vary. Bonafide prices are the published direct charges.
What the “monthly” plan actually means
The arithmetic is simple:
- At one insert every three nights, 10 inserts × 3 nights = 30 nights.
- At one insert every two nights, 10 inserts × 2 nights = 20 nights.
So “monthly” is true only at the less-frequent end of the label schedule. Someone using it every two nights needs about 15 inserts for 30 days, not 10.
That changes the lived cash cost:
| Use frequency | Inserts needed for 30 days | Fixed no-renewal retail combination | Approximate 30-day product cost |
|---|---|---|---|
| Every 3 nights | 10 | One Target 10-count box | $47.99 |
| Every 2 nights | 15 | One Target 10-count + one Target 5-count | $74.98 |
Those are arithmetic planning figures, not dosing advice. Follow the product instructions or your clinician's instructions.
The 12-week study horizon costs more than a trial box
The strongest product-specific pilot measured its main outcome at 12 weeks — 84 days. To reach that same time horizon at the label schedule, the arithmetic is:
| Frequency | Inserts for 84 days | Closest no-renewal Target quantity | Cash required at current Target prices |
|---|---|---|---|
| Every 3 nights | 28 | Three 10-count boxes = 30 inserts | $143.97 |
| Every 2 nights | 42 | Four 10-count boxes + one 5-count = 45 inserts | $218.95 |
A five-count box cannot tell you whether Revaree works over the study horizon. It can tell you whether insertion, melting, residue, bedtime timing, and the base formula feel tolerable enough to justify buying more.
Which option is actually cheapest?
The answer depends on what “cheap” means:
- Least cash at risk before you know whether you tolerate it: Target 5-count, $26.99.
- Lowest live quoted unit price on our verification date: SingleCare's estimated $36.78 for 10 with the one-time $3 signup bonus, or $3.68 each.
- Lowest fixed direct unit price: Bonafide every-six-month plan, $222 upfront, or $3.70 each.
- Best fixed direct balance after the product proves itself: Bonafide quarterly, $129 upfront, or $4.30 each.
- Worst fixed unit value: Bonafide one-time direct, $68 delivered, or $6.80 each.
The previous assumption that a discount card could not beat the long subscription was wrong on the live September 2 quote. It did — by two cents per insert after the one-time signup bonus. The catch is predictability. A Bonafide subscription price is published and fixed until the seller changes it; a coupon quote can move by location, pharmacy, or date.
The subscription “savings” are real — and they buy commitment
Compared with the $63 one-time product price before shipping:
- Monthly saves $16 per 10 inserts.
- Quarterly saves $18 per 10-insert equivalent.
- Six-month saves $26 per 10-insert equivalent.
The biggest percentage belongs to the biggest commitment. That discount is not free money. It is compensation for putting $222 on the card before the next six months have happened.
Does insurance cover Revaree?
Bonafide says Revaree is not covered by traditional insurance. Because it is sold without a prescription, standard prescription-drug coverage is not the usual route.
Bonafide offers an HSA/FSA eligibility process through Truemed. The buyer completes a health survey and a licensed provider reviews it. Bonafide says an approved letter of medical necessity typically arrives within 48 hours. Approval and reimbursement are not guaranteed; your plan administrator controls your account.
Our cost verdict
Do not begin with Bonafide's six-month plan simply because it has the lowest fixed direct unit cost. Buy the smallest no-renewal quantity that can answer the question in front of you.
- Need to learn whether you can tolerate the format? Five inserts can answer that.
- Need enough product for the brand's day-30 checkpoint? Plan for 10 inserts at every-three-night use or 15 at every-two-night use.
- Already know it works and want a published, predictable direct price? Quarterly is the cleaner balance.
- Certain you will use it for six months and comfortable with direct return limits? Then the six-month unit price becomes relevant.
That ordering protects the buyer from confusing a lower unit price with a lower-risk decision.
Is Revaree Plus worth paying more for?
Revaree Plus doubles the listed hyaluronic-acid amount from 5 mg to 10 mg and adds sweet almond oil. It also raises every verified direct price. The public evidence does not establish that Plus works better than original Revaree, and its FDA clearance did not include condom-compatibility testing. Skip Plus if you have a known almond allergy or sensitivity.
Revaree Plus is not merely a larger box. It is a different device record and a different formula.
| Feature | Original Revaree | Revaree Plus |
|---|---|---|
| Hyaluronic acid per insert | 5 mg | 10 mg |
| Added oil | None listed | Sweet almond oil |
| FDA clearance | K153372 | K213220 |
| Condom testing in FDA summary | Tested; incompatible with natural rubber latex, polyurethane, and polyisoprene | Not conducted; labeling says not compatible with those materials |
| One-time direct | $63 + $5 shipping | $65 + $5 shipping |
| Monthly | $47 | $52 |
| Quarterly | $129 | $141 |
| Every 6 months | $222 | $246 |
| Evidence base | Small randomized 12-week pilot for a 5 mg insert plus broader HA-category evidence | Small four-week open-label, uncontrolled study reported as a conference abstract |
Prices verified September 2, 2026. Subscriptions included free standard shipping; one-time direct orders listed $5 standard shipping.
At 10 inserts per box, Plus costs $5 more monthly, $12 more quarterly, and $24 more every six months. That is not a huge dollar gap. It is still a premium without comparative evidence showing that the added 5 mg or almond oil produces a better result.
The preliminary Plus study is useful for signal, not for a superiority verdict. It was short, open-label, and uncontrolled. Without a randomized original-versus-Plus comparison, there is no clean answer to “is double the hyaluronic acid twice as effective?” The evidence does not establish that.
Our decision rule is blunt: start with original Revaree unless you have a specific reason to prefer the Plus formula and no almond sensitivity. Paying more because “double” sounds stronger is not evidence.
How long does Revaree take to work?
Separate three questions. Five inserts can reveal whether you tolerate the format over roughly 10 to 15 days. Bonafide markets relief in as little as nine days and 91% by day 30. The strongest product-specific randomized pilot evaluated the main outcome at 12 weeks. Those are three different checkpoints, not one guaranteed timeline.
The most honest timeline is not “wait eight weeks” and not “you will feel it in nine days.” It is a sequence of decisions.
Revaree decision timeline
| Checkpoint | What you can reasonably learn | What you cannot conclude yet |
|---|---|---|
| First use | Whether insertion is manageable and whether immediate burning or irritation occurs | Whether recurring dryness will improve over time |
| 10–15 days | Whether a five-count box is tolerable; whether melting, residue, and bedtime use fit your life | Whether the product works through the trial's 12-week endpoint |
| Day 30 | Whether you match the brand's stated “91% by day 30” checkpoint; whether continuing feels justified | That your result will persist or match vaginal estrogen |
| Week 12 | The endpoint used in the strongest product-specific randomized pilot | Long-term durability or rare safety problems |
Bonafide says relief can occur in as little as nine days. That is possibility language, not a promise. A five-count Target box lasts 10 days at every-two-night use or 15 days at every-three-night use, so it overlaps the brand's earliest claim. It still does not establish a dependable response.
When to stop waiting
Stop the product and contact a clinician if the discomfort continues or the symptoms worsen, following the product instructions. Stop sooner for burning, irritation, or another reaction that concerns you.
Do not wait for a moisturizer to solve bleeding, fever, pelvic pain, a sore, a lump, unusual discharge, or urinary symptoms that could represent another condition. Those need evaluation, not a longer subscription.
If the format is tolerable but there is no meaningful benefit by the checkpoint you and your clinician chose, reassess the route. For someone with classic GSM tissue symptoms, prescription local vaginal estrogen may be the more effective next discussion. For someone with urinary symptoms or recurrent UTI, the 2025 guideline gives vaginal estrogen — not moisturizers — the stronger role.
Revaree vs vaginal estrogen: which one fits your symptoms?
Choose Revaree when the problem is mainly vaginal dryness, you want to avoid hormones, and you accept ongoing moisturizer use. Ask about FDA-approved local vaginal estrogen when symptoms include recurrent UTIs, urgency, frequency, leakage, persistent painful sex, or a moisturizer has not been enough. Generic prescription pricing can be lower than Revaree's recurring cash cost.
This is not a contest between a “natural” product and a “strong” product. They do different jobs.
A moisturizer can reduce friction and support hydration while you use it. The 2025 AUA/SUFU/AUGS guideline says clinicians should recommend vaginal moisturizers and/or lubricants — alone or with other treatments — for vulvovaginal dryness and/or dyspareunia. The recommendation is moderate, with Grade C evidence.
The same guideline says local low-dose vaginal estrogen should be offered for vulvovaginal discomfort due to GSM and recommends it for GSM with recurrent UTIs when there are no contraindications. It also says moisturizers do not address the underlying tissue changes of GSM and that evidence does not show they improve urinary urgency, frequency, leakage, or recurrent UTI prevention.
Symptom-to-option map
| Your dominant problem | Revaree fit | Vaginal-estrogen conversation | Why |
|---|---|---|---|
| Dryness only | Reasonable first option | Also reasonable if appropriate | Both can improve vaginal symptoms; preference and risk context matter |
| Dryness plus pain with sex | Reasonable if friction/dryness seems central | Worth discussing if pain persists | Moisturizer may help friction; persistent pain may need tissue-directed treatment or another diagnosis |
| Recurrent UTIs with GSM | Not the evidence-backed first choice | Stronger fit | Guideline recommends local low-dose vaginal estrogen for reducing future UTIs when appropriate |
| Urgency, frequency, or leakage | Weak fit as a stand-alone answer | Discuss evaluation and treatment options | Moisturizer evidence does not support a urinary-symptom claim |
| You cannot or do not want to use hormones | Stronger fit | Decision depends on the reason and clinical context | Revaree contains no listed hormone |
| A moisturizer has already failed | Low | Stronger reason to ask | Continuing the same category may not close the gap |
| You rely on affected condom materials | Poor fit | Ask about compatible options | Revaree's warning covers natural rubber latex, polyurethane, and polyisoprene |
| Unexplained bleeding, fever, pelvic pain, sore, lump, or unusual discharge | Do not self-treat first | Evaluation first | The immediate job is finding the cause |
Cost changes the answer more than people expect
Revaree is sold without a prescription, but access is not the same thing as low long-term cost. On September 2, 2026:
- Cost Plus Drugs listed generic estradiol 0.01% vaginal cream, 42.5 g, at $13.21 before shipping and applicable fees.
- SingleCare displayed a generic estradiol coupon quote around $32.51 with a one-time $3 signup bonus; pharmacy and location affect the price.
- Revaree's published fixed direct prices ranged from $47 for 10 inserts monthly to $222 for 60 inserts every six months.
Those figures are not an apples-to-apples treatment comparison. Vaginal estrogen requires a prescription, directions vary, and the amount used can include a loading phase followed by maintenance. Still, they break the assumption that “prescription” automatically means “more expensive.”
A 42.5 g tube contains 42.5 one-gram amounts. At a maintenance schedule of 1 g twice weekly, that arithmetic is roughly 21 weeks of doses — but the prescribed dose and loading phase can change the real duration. Do not use that calculation to set your own regimen.
FDA-approved is not the same as compounded
FDA-approved vaginal-estrogen products have FDA-reviewed labeling and manufacturing controls. Compounded vaginal estrogen is not FDA-approved. A compounded product should never be described as equivalent, “the same,” or clinically proven merely because a label lists a familiar ingredient.
For a brand-name or FDA-approved vaginal-estrogen decision, use a provider that can prescribe FDA-approved products when they are appropriate. Compare online menopause and HRT providers or read our guide to vaginal estrogen before a consult.
Our decision rule
If your only problem is recurring dryness and you want to avoid hormones, Revaree earns a reasonable first try.
If the problem includes urinary symptoms, recurrent UTIs, persistent pain, or a moisturizer that already failed, stop treating “hormone-free” as the only decision variable. The better question is which route matches the symptom you actually need to solve.
Source: AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, 2025. Price pages rechecked September 2, 2026.
Who should skip Revaree or get checked first?
Skip self-treatment and get evaluated first for unexplained vaginal bleeding, unusual discharge, fever, pelvic or abdominal pain, a new lump or sore, or severe or worsening pain. Revaree is also a poor fit if you rely on the condom materials in its warning. Pregnancy, breastfeeding, cancer history, and persistent urinary symptoms deserve individualized guidance rather than a checkout-page answer.
The page matters most here. “Hormone-free” can sound like permission to treat any symptom without asking what is causing it. That is not what the label or evidence supports.
Get evaluated before buying
Seek clinical evaluation before using an over-the-counter moisturizer as the answer if you have:
- unexplained vaginal or postmenopausal bleeding
- unusual or foul-smelling discharge
- fever or chills
- pelvic or abdominal pain
- a new lump, sore, ulcer, or skin change
- severe pain, rapidly worsening pain, or pain unrelated to dryness
- new urinary burning, blood in the urine, repeated UTIs, or difficulty urinating
- symptoms that started suddenly or feel different from your usual pattern
Those symptoms can have causes a moisturizer cannot diagnose or treat.
Ask before using if this applies to you
- You are pregnant or breastfeeding. Revaree's instructions say to use it under a doctor's supervision during pregnancy and not to use it while breastfeeding without consultation.
- You are using another vaginal product. Revaree's instructions say interactions with other vaginally administered products have not been established.
- You have a history of breast, uterine, ovarian, or another hormone-sensitive cancer. Revaree is hormone-free, which may be attractive, but the cause of the symptom and your full treatment plan still matter.
- You have pelvic-floor pain, vulvar skin disease, recurrent infection, or symptoms that did not improve with a moisturizer.
- You have a known almond allergy or sensitivity and are considering Revaree Plus.
This does not automatically make Revaree unsafe
Cancer history does not turn a hormone-free moisturizer into a hormone product. The point is not to frighten someone away from a nonhormonal option. It is to avoid allowing a broad “safe for everyone” claim to replace individualized care or delay evaluation.
A fast routing rule
| Situation | Better next move |
|---|---|
| Dryness only; no red flags; condom warning does not affect you | A small no-renewal Revaree trial is reasonable |
| Dryness plus urinary urgency, frequency, leakage, or recurrent UTI | Clinical evaluation and a local-vaginal-estrogen discussion if appropriate |
| Severe or worsening pain, bleeding, fever, unusual discharge, sore, or lump | In-person evaluation before self-treatment |
| Product burns or irritates | Stop using it and contact a clinician if symptoms persist or concern you |
| Product is tolerable but not helping by your chosen checkpoint | Reassess rather than auto-renewing indefinitely |
What side effects or complaints can Revaree cause?
The published instructions tell users to stop for burning, discomfort, or another reaction and to contact a doctor if discomfort persists or symptoms worsen. The randomized pilot was too small to establish rare-event rates. FDA's MAUDE database contains at least three brand-name reports we located, but MAUDE reports cannot prove that Revaree caused an event or calculate how often it happens.
The first useful distinction is between expected product behavior, an intolerable reaction, and an event report.
Expected behavior is not the same as a side effect
Revaree is a solid insert in a glyceride base. It melts after insertion. Bonafide recommends bedtime use and says to remain lying down for 30 minutes. Some residue or leakage can happen.
That may be annoying enough to stop using it. It is still different from burning, swelling, rash, fever, pelvic pain, urinary infection symptoms, or another concerning reaction.
What the label tells you to do
The current instructions say:
- stop using the product in the event of burning, discomfort, or any other adverse reaction
- contact a doctor if discomfort continues or symptoms worsen
- keep the product away from children
- do not use it as contraception or as a spermicide
- do not use it after the expiration date or if the individual packaging is damaged
The instructions also say adverse events should be reported to the manufacturer and FDA.
What the randomized pilot tells us
The 2024 pilot did not report treatment-related serious adverse events. That is reassuring within a very small study. It does not establish a dependable rate for infection, irritation, or a rare event in the much larger population using the product outside a trial.
What FDA's MAUDE database does — and does not — show
We located three brand-name reports involving Revaree or Revaree Plus:
| Report timing | Product named | What the report describes | What can be concluded |
|---|---|---|---|
| 2021 report | Revaree | Burning and discontinuation in a 62-year-old user | The event was reported. Causation and frequency cannot be established from MAUDE. |
| Event in November 2022; report filed in 2023 | Revaree | Vaginal infection, UTI, kidney infection, fever, emergency care, and a near-sepsis description; the report says product contribution could not be ruled out | Serious symptoms were reported after use. The report does not prove that Revaree caused them. |
| Report received May 2025 | Revaree Plus | A 71-year-old user with malaise, tachycardia, a positive UTI test, emergency evaluation, IV fluids, and antibiotics | The event was reported after use. It does not establish causation or an incidence rate. |
FDA warns that MAUDE reports are incomplete, may be unverified, can be duplicative, and do not by themselves establish that a device caused an event. The number of products used is also unknown, so the database cannot produce a risk rate.
That means two opposite claims are both unjustified:
- “Three reports prove Revaree causes UTIs.”
- “Only three reports means the risk is negligible.”
The honest conclusion is narrower: serious events have been reported after brand-name use; causation and frequency are unknown; burning, persistent discomfort, urinary symptoms, fever, or worsening pain should not be brushed off as a normal adjustment.
Stop versus urgent evaluation
| What is happening | Practical next step |
|---|---|
| Mild residue or leakage without pain | Use at bedtime, stay lying down for the recommended period, and decide whether the inconvenience is acceptable |
| Burning, irritation, rash, or discomfort after insertion | Stop the product; contact a clinician if it persists, worsens, or concerns you |
| Fever, flank pain, severe pelvic pain, vomiting, faintness, rapid heart rate, or feeling acutely unwell | Seek prompt medical care rather than waiting for the product to “settle” |
| New urinary burning, frequency, urgency, blood in urine, or recurrent infection symptoms | Get evaluated for a urinary problem; do not assume dryness is the cause |
| Bleeding, unusual discharge, a sore, or a lump | Clinical evaluation before resuming self-treatment |
Source: Revaree instructions for use, Agrawal et al. 2024, and FDA's MAUDE database limitations.
Can you use Revaree with condoms?
Not with natural rubber latex, polyurethane, or polyisoprene condoms. Original Revaree was tested and found incompatible with all three materials. Revaree Plus did not undergo condom-compatibility testing, and its current labeling also says it is not compatible with those materials. Neither product is contraception or a spermicide. Resolve your barrier plan before buying.
Do not reduce this warning to “avoid latex.” Polyurethane and polyisoprene are also named.
| Barrier material | Original Revaree | Revaree Plus | What to do |
|---|---|---|---|
| Natural rubber latex condom | Not compatible | Not compatible | Do not combine without qualified contraceptive or sexual-health guidance |
| Polyurethane condom | Not compatible | Not compatible | Do not assume “latex-free” solves the issue |
| Polyisoprene condom | Not compatible | Not compatible | Do not combine without guidance |
| Other barrier material or device | Not established by the cited product records | Not established by the cited product records | Check the exact barrier's instructions and ask a pharmacist or clinician |
The FDA summary for original Revaree says condom-compatibility testing was performed and found incompatibility with the three named materials. The Plus summary says testing was not conducted because the formulation contains oil and would not be compatible; the current Plus instructions carry the same warning.
The product instructions do not specify a tested waiting interval after use that makes one of those condoms compatible. Do not invent one.
If condoms are part of pregnancy prevention or STI protection, this is a decision-stopping fact, not a footnote. Choose a product or plan with compatibility you can verify first.
How do you use Revaree correctly?
Wash your hands, remove one insert from its individual packaging, and place it into the vagina with a clean finger. Use one insert every two to three nights, preferably at bedtime, unless your clinician says otherwise. Bonafide says to remain lying down for 30 minutes. Do not cut, reuse, swallow, or use damaged or expired inserts.
The format is one of Revaree's strongest selling points: no applicator, no measured cream, and no prescription. The tradeoff is that a melting base can create residue or leakage.
Step by step
- Read the package and check the product. Confirm it is the formula you intended to buy, check the expiration date, and do not use an insert if its individual package is damaged.
- Wash and dry your hands. A clean finger is the applicator.
- Remove one insert from the blister or individual wrapper. Do not swallow it.
- Insert it gently into the vagina. Do not force it through pain.
- Use it at bedtime when practical. Bonafide says to remain lying down for 30 minutes after insertion.
- Repeat every two to three nights. Do not treat the schedule as a reason to use more often than the instructions or your clinician recommends.
- Stop for burning, discomfort, or another reaction. Contact a clinician if discomfort continues or symptoms worsen.
What to expect after insertion
The insert melts. Some residue or discharge the next morning can be an ordinary feature of the dosage form. A liner may protect clothing or bedding if that matters to you.
Residue is not permission to re-dose. The amount left on a liner does not tell you how much was absorbed or whether another insert is needed.
What not to combine casually
The instructions say interactions with other vaginally administered products have not been established. That includes the possibility of using Revaree near another moisturizer, prescription vaginal medication, antifungal, spermicide, contraceptive product, or pelvic treatment.
Ask a pharmacist or clinician how to separate products rather than creating your own timing rule.
Storage
Follow the temperature and packaging directions on your current carton and instructions. Keep inserts in their individual packaging until use, away from children, and do not use after the expiration date.
When insertion itself is painful
Do not keep forcing an insert because the product is sold over the counter. Pain with insertion can reflect dryness, pelvic-floor tension, narrowing, a skin condition, infection, or another issue. A clinician can help separate those possibilities.
Is the Revaree subscription easy to cancel or return?
Bonafide says subscriptions can be canceled through your account, by phone, or by email, but cancellation must occur at least five business days before the next processing date. Direct returns are limited to unopened, unused product: first orders within 30 days of shipment and recurring orders within 14 days, with a $7 return-shipping deduction.
This is the other reason not to begin with six months.
Direct cancellation rules
| Policy item | What Bonafide publishes |
|---|---|
| How to cancel | Online account, phone, or email |
| Deadline | At least five business days before the next processing date |
| What happens after the deadline | The next order may already process and ship |
| Subscription price changes | Terms allow prices to change; review renewal notices and account details |
A calendar reminder seven or more business days before renewal gives you room to decide before the stated cutoff. That is an editorial planning suggestion, not a seller guarantee.
Direct return rules
| Order type | Return window | Product condition | Deductions and timing |
|---|---|---|---|
| First direct order | Within 30 days of shipment | Unopened and unused | $7 deducted for return shipping; ship the label within 14 days of receiving it |
| Recurring direct order | Within 14 days | Unopened and unused | Same $7 deduction and label-shipment condition |
| Opened product | Not eligible under the published direct policy | — | A reaction after opening does not create a published money-back guarantee |
Bonafide says refund processing takes three to five business days and asks customers to allow up to 10 days for the credit to appear.
Why the open-box rule changes the first purchase
A product can be impossible to evaluate without opening it. If you react to the first insert or hate the format, the remaining opened package is not eligible under Bonafide's published direct return policy.
That makes Target's five-count box more than a convenience size. It limits how much cash sits behind an unreturnable open package.
Target's current listing displayed a 90-day return window. That does not mean every opened personal-care item is guaranteed to be accepted. The item page, complete Target return policy, purchase method, condition, and retailer decision control.
Subscription exit checklist
- Save the order confirmation and renewal date.
- Set a reminder more than five business days before processing.
- Cancel through the method you can document.
- Keep the confirmation email or account screenshot.
- If returning an eligible unopened box, request the label within the published window and ship it within 14 days of receiving the label.
- Do not rely on an opened-product satisfaction guarantee; none appears in the current direct policy.
Sources: Bonafide Terms & Conditions and Return Policy, rechecked September 2, 2026.
What do real Revaree reviews reveal?
Public reviews are most useful for identifying friction, not proving efficacy. Target's listing displayed 4.54 out of 5 across 1,362 ratings, but many reviews were syndicated from Bonafide. The same page showed lower quality and value subratings. Recurring complaints centered on packaging, residue, price, and the short “month” supply.
A high average can coexist with a product that is expensive, messy, or poorly matched to a specific symptom. The star number alone does not resolve those questions.
Review provenance matters
On September 2, 2026, Target displayed:
| Target review signal | Displayed result |
|---|---|
| Overall rating | 4.54 / 5 |
| Number of ratings | 1,362 |
| Quality subrating | 3.54 / 5 |
| Value subrating | 3.27 / 5 |
Many entries were marked “originally posted on hellobonafide.com.” That does not make them fake. It means Target's review count is not a clean, independent Target-only sample.
We do not turn that seller-displayed average into a The HRT Index score, and we do not use Review or AggregateRating schema for this editorial page.
The complaints that change a buying decision
“Love the product. Hate the packaging.” — Donna S., review syndicated from Bonafide to Target, August 19, 2026.
That is a usability complaint. It says nothing about a treatment effect, but it matters because the package is opened repeatedly and each insert must stay intact.
“The ‘month’ supply is short.” — Aimee R., review syndicated from Bonafide to Target, July 22, 2026.
That complaint is supported by the label math. At every-two-night use, 10 inserts last 20 days. The review does not establish the schedule; the current product directions do.
Other recurring themes across retailer and seller reviews include:
- residue or leakage after the insert melts
- dislike of the wrapper or opening process
- recurring cost
- relief that the format is hormone-free and applicator-free
- disappointment when results were slower or smaller than expected
We do not quote reviews to create an efficacy claim. Voluntary reviews have selection bias, unknown adherence, unknown diagnoses, and no control group.
What to take from the reviews
Treat packaging, leakage, renewal frustration, and “month supply” complaints as operational signals. Treat “it cured me,” “it never works,” and star averages as individual experiences unless stronger evidence supports the same conclusion.
That is the useful split: trial data for average effects; labels and policies for safety and money; reviews for what daily use can feel like.
Where should you buy Revaree?
Buy the smallest no-renewal amount first. Target's five-count box required the least verified cash at $26.99. A live SingleCare quote offered the lowest estimated unit price, but coupon prices can move. Once Revaree has proved both tolerable and useful, Bonafide's quarterly plan offers the cleaner fixed direct balance of unit cost and commitment.
There is no universal cheapest route because the choice changes between first purchase, reliable refill, and lowest possible coupon quote.
| Your situation | Best-fit route | Why | Catch |
|---|---|---|---|
| You have never used Revaree | Target 5-count | Lowest fixed cash commitment; no renewal | Only 10–15 days at the published schedule; tests format better than efficacy |
| You want 10 inserts without renewal | Check Target and live local coupon quotes | Target is predictable; coupon quote may be cheaper | Stock, pharmacy participation, and coupons change |
| You already know it works and want a stable direct plan | Bonafide quarterly | $4.30 per insert, 30 inserts, less commitment than six months | $129 charged at once; auto-renews |
| You prioritize the lowest fixed direct unit price | Bonafide every six months | $3.70 per insert | $222 upfront; auto-renews; direct opened-product returns unavailable |
| You need the least expensive route on a specific day | Compare SingleCare and local pharmacy checkout | Live quote can beat the subscription unit price | Estimated, location-dependent, not guaranteed |
| You are considering Plus | Start by asking what original Revaree failed to do | Plus costs more and has no superiority trial | Almond sensitivity and same practical condom warning |
Do not buy from an unfamiliar marketplace seller just to save a few dollars
This is a packaged vaginal device with an expiration date, storage requirements, and individual seals. Confirm the seller, lot integrity, package condition, return terms, and expiration date. A damaged wrapper is a do-not-use condition in the instructions.
The no-regret buying sequence
- Check the contraindication and condom issues first. A low price is irrelevant if the product does not fit your barrier plan or your symptoms need evaluation.
- Buy five inserts when the first question is format tolerance. That limits cash exposure.
- Use the published schedule. Do not accelerate the schedule to force a fast answer.
- Choose a checkpoint before renewing. Day 30 is the brand's public claim; week 12 is the strongest product-specific trial endpoint.
- Only then optimize unit cost. Quarterly is our fixed direct balance; six months is for someone already certain.
This is the conversion point the seller cannot resolve for you: the best first purchase and the best refill are not the same product decision.
Final verdict: Is Revaree worth it?
Revaree is worth a small, no-renewal first purchase for recurring vaginal dryness when you want a hormone-free insert, accept the recurring cost, and do not rely on the condom materials in its warning. It is not worth treating as an estrogen equivalent, a urinary-symptom treatment, or a reason to delay evaluation of bleeding, infection signs, or severe pain.
We came into this review skeptical of two things: the easy slide from FDA-cleared to “FDA approved,” and the easy slide from a 10-count box to “one month.” Both needed correction.
The product still came out with a legitimate place.
What Revaree earns
- A traceable Class II FDA device clearance for the underlying original insert
- A clearly hormone-free listed formula
- A no-prescription, applicator-free format
- Encouraging product-specific randomized evidence, even though the study is small
- Broader evidence that vaginal hyaluronic acid can help dryness
- A five-count retail option that limits the first cash commitment
What it does not earn
- FDA-approved-drug language
- A claim of equivalence to vaginal estrogen
- A urinary urgency, frequency, leakage, or recurrent-UTI claim
- A blanket “safe for everyone” claim
- A reliable “month” promise at every-two-night use
- A free pass on the condom warning
- A reason to spend $222 before finding out whether the format works for you
The decision in one table
| Your situation | Our verdict | Next action |
|---|---|---|
| Recurring dryness only; hormone-free matters; no red flags; condom warning does not affect you | Reasonable first try | Start with a five-count no-renewal box |
| You tolerate it and see enough benefit to continue | Optimize the refill, not the first purchase | Compare a live coupon quote with Bonafide quarterly |
| Urinary urgency, frequency, leakage, or recurrent UTI is part of the problem | Wrong stand-alone tool | Ask about diagnosis and FDA-approved local vaginal estrogen if appropriate |
| A moisturizer has failed or sex remains painful | Do not keep renewing by inertia | Reassess the diagnosis and treatment route |
| You use natural rubber latex, polyurethane, or polyisoprene condoms | Poor fit until protection is resolved | Choose a verified compatible route with professional guidance |
| Bleeding, fever, unusual discharge, severe pain, sore, or lump | Do not self-treat first | Get evaluated |
| You want Plus because 10 mg sounds stronger | Premium not yet justified by comparative evidence | Start with original unless a specific reason supports Plus |
Our bottom line: Revaree is a credible moisturizer, not a miracle and not HRT. Buy the minimum that answers your first question. Give it a defined checkpoint. Keep the condom warning visible. And when the symptom pattern points beyond dryness, move to the route with evidence for the problem you actually have.
For an individualized online-care route — including the safety flag for cases that should start in person — use Find My HRT Path. The result should make the next consult more specific, not replace one.
Revaree FAQ
Is Revaree a hormone?
No. The current original Revaree formula lists 5 mg of hyaluronic acid sodium salt in a semi-synthetic glyceride base. Hyaluronic acid is not estrogen, progesterone, testosterone, or another hormone. Revaree is a vaginal moisturizer and personal-lubricant device, not HRT.
Is Revaree FDA approved?
No. Original Revaree is linked to FDA-cleared Class II device record K153372. Revaree Plus is FDA-cleared under K213220. FDA clearance through 510(k) is not FDA approval of a drug, and neither record proves that the product treats every symptom of genitourinary syndrome of menopause.
Does Revaree work as well as vaginal estrogen?
The current evidence cannot prove that. A small 2024 randomized pilot found improvement in both a 5 mg hyaluronic-acid-insert group and a vaginal-estrogen group, with no detected difference on the main symptom score at 12 weeks. It was not designed as a definitive equivalence or noninferiority trial.
How often do you use Revaree?
The current instructions say one insert every two to three nights, preferably at bedtime, unless a clinician directs otherwise. Bonafide says to remain lying down for 30 minutes after insertion. Do not use more often to force a faster result.
How long does a 10-count box last?
About 20 days at one insert every two nights or 30 days at one every three nights. That is why “one-month supply” is accurate only at the less-frequent end of the published schedule.
How long does Revaree take to work?
Bonafide markets relief in as little as nine days and says 91% experienced relief by day 30. Those are brand-published claims, not guarantees. The strongest product-specific randomized pilot measured its main result at 12 weeks. Five inserts can test tolerability over 10 to 15 days, not prove a 12-week outcome.
Can Revaree cause burning?
Burning has been reported, and the instructions tell users to stop for burning, discomfort, or another adverse reaction. Contact a clinician if discomfort continues, worsens, or concerns you. Fever, severe pain, urinary symptoms, bleeding, or feeling acutely unwell needs more than a wait-and-see approach.
Can Revaree cause a UTI?
FDA's MAUDE database includes reports in which urinary infections or related symptoms occurred after Revaree or Revaree Plus use. Those reports do not establish that the product caused the events or show how often they occur. New urinary burning, urgency, frequency, fever, or flank pain should be evaluated.
Can I use Revaree with latex condoms?
No. Original Revaree was tested and found incompatible with natural rubber latex, polyurethane, and polyisoprene condoms. Revaree Plus was not compatibility-tested, and its labeling carries the same not-compatible warning. “Latex-free” is not enough if the alternative is polyurethane or polyisoprene.
Is Revaree a spermicide or birth control?
No. The instructions say it is not a contraceptive and does not contain spermicide. Do not rely on it to prevent pregnancy or sexually transmitted infection.
Can Revaree be used with vaginal estrogen?
Do not create your own combination schedule. Revaree's instructions say interactions with other vaginally administered products have not been established. A clinician or pharmacist can tell you whether both are appropriate and how to separate them.
Can I use Revaree after breast cancer?
Revaree contains no listed hormone, which is one reason some women consider it. A cancer history still deserves individualized guidance because the cause of symptoms, other treatments, and the full care plan matter. Hormone-free does not mean every symptom should be self-diagnosed.
Can I use Revaree while pregnant or breastfeeding?
The current instructions say to use it under a doctor's supervision during pregnancy and not to use it while breastfeeding without consulting a doctor. Ask before use.
What is the difference between Revaree and Revaree Plus?
Original Revaree contains 5 mg of hyaluronic acid per insert. Plus contains 10 mg and adds sweet almond oil. Plus costs more and should be avoided with a known almond allergy or sensitivity. Current evidence does not establish that Plus works better than original Revaree.
Does insurance cover Revaree?
Bonafide says traditional insurance does not cover it. The company offers an HSA/FSA eligibility process through Truemed, but a letter of medical necessity and reimbursement are not guaranteed. Your plan administrator makes the final decision.
Can I return Revaree after opening it?
Not under Bonafide's published direct return policy. Direct returns must be unopened and unused. First orders have a 30-day window from shipment; recurring orders have a 14-day window; a $7 return-shipping deduction applies. Target's item page displayed a 90-day return window, but the complete Target policy and actual item eligibility control.
How do I cancel a Revaree subscription?
Bonafide says you can cancel through your account, by phone, or by email. Do it at least five business days before the next processing date. Save the confirmation because a cancellation after the cutoff may not stop the next shipment.
What is the cheapest way to try Revaree?
The lowest fixed cash commitment we verified was Target's five-count box at $26.99. A live SingleCare quote showed a lower estimated unit price for 10 inserts, but the coupon price can change by pharmacy, location, and date. For a first purchase, lower cash at risk matters more than the lowest unit cost.
When should I choose vaginal estrogen instead?
Ask about FDA-approved local vaginal estrogen when urinary urgency, frequency, leakage, recurrent UTIs, persistent pain with sex, or a failed moisturizer is part of the picture. The 2025 GSM guideline gives vaginal estrogen a stronger role for several of those situations than it gives moisturizers.
Sources and verification register
The links below are the evidence base for this page. Commercial pages and prices were rechecked September 2, 2026. Medical and regulatory sources are linked to the current official or indexed record available on that date.
- U.S. Food and Drug Administration. 510(k) Summary K153372 — Repagyn vaginal suppositories. Decision June 30, 2016.
- U.S. Food and Drug Administration. 510(k) Summary K213220 — Revaree Plus vaginal suppositories. Decision June 21, 2022.
- U.S. National Library of Medicine. AccessGUDID record for Revaree.
- U.S. Food and Drug Administration. Premarket Notification 510(k).
- Bonafide Health. Revaree product page. Rechecked September 2, 2026.
- Bonafide Health. Revaree instructions for use. Revision displayed 2024.
- Bonafide Health. Revaree Plus product page. Rechecked September 2, 2026.
- Bonafide Health. Revaree Plus package insert.
- Bonafide Health. Terms & Conditions. Rechecked September 2, 2026.
- Bonafide Health. Return Policy. Rechecked September 2, 2026.
- Bonafide Health. FSA/HSA information. Rechecked September 2, 2026.
- Agrawal S, et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for GSM. Menopause. 2024;31(9):750–755.
- PubMed. Indexed record for Agrawal et al..
- ClinicalTrials.gov. NCT04544475.
- American Urological Association, Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, and American Urogynecologic Society. Genitourinary Syndrome of Menopause Guideline, 2025.
- Chen J, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness. J Sex Med. 2013.
- Target. Bonafide Revaree 5-count listing. Rechecked September 2, 2026.
- Target. Bonafide Revaree 10-count listing. Rechecked September 2, 2026.
- SingleCare. Revaree discount page. Quote rechecked September 2, 2026; local and time-sensitive.
- SingleCare. Estradiol vaginal cream discount page. Quote rechecked September 2, 2026; local and time-sensitive.
- Mark Cuban Cost Plus Drug Company. Estradiol cream product page. Price rechecked September 2, 2026.
- U.S. Food and Drug Administration. About the MAUDE database and its limitations.
- U.S. Food and Drug Administration. Manufacturer and User Facility Device Experience database.
- The HRT Index. Vaginal estrogen guide.
- The HRT Index. Best online HRT providers for menopause.
- The HRT Index. Find My HRT Path.
This page is independent editorial research. It is not medical advice, not a diagnosis, not a substitute for a clinician, and not medically reviewed by a clinician. Prices, policies, stock, and coupon quotes can change; the verification date appears at the top so you can judge freshness.